Try our Advanced Search for more refined results
Life Sciences - April, 2021
347 articles
- PE Firms Want Out Of Pot RICO Suit Against Harvest, Verano
- NY Panel Sustains 1933 Act Claims For 1st Time Post-Cyan
- COVID IP Waiver Plan At WTO Being Revised Amid 'Optimism'
- The Big Picture: Opioid MDL's 1st Bellwether Gets Underway
- Robbins Geller, Pomerantz To Lead AstraZeneca Investor Suit
- Mass. Judge Says Heart Monitor Patent Validity Isn't Clear Yet
- W.Va. Senators Bid Again For More Opioid Oversight
- 11th Circ. Questions Fla. Medical Pot License Law
- Judge Won't OK Coppertone Buyers' $2.25M False Ad Deal
- Bausch Lobs IP Suit At Mylan Over Planned Trulance Generic
- Health Hires: Istari Oncology, Dykema, Paul Hastings
- COVID Vaccine Maker, Cancer Biotech IPOs Total $231M
- CVS Hand Sanitizer Buyers Win Certification In False Ad Suit
- Bankruptcy Watchdog Bares Teeth At BigLaw In Purdue Ch. 11
- Drug Cos. In Opioid Bellwether Deny Any Duty To Halt Orders
- 5 Key Details As Clock Ticks Down To Opioid MDL's 1st Trial
- IP Forecast: PTAB Fee Bias Claims & Uggs At The Fed. Circ.
- Nebraska Sheriff Accused Of Breaking Law With Pot Lawsuit
- 2nd Circ. Revives Challenge To Nursing Home Inspection Rule
- AOP Orphan Wins €140M Award From Taiwanese Pharma Co.
- Array Biopharma, Investors Agree To $8.5M Settlement Deal
- Celgene Sues Hikma To Block Revlimid Generic
- FDA To Ban Menthol Cigarettes, Cigar Flavors
- Fed. Circ. OKs ITC Ruling That Bio-Rad Infringed 10x Patents
- House Reps Want State Pot Laws Protected In Budget
- Deals Rumor Mill: Carlyle, Ant Group, Freshworks
- 3 Firms Give Up $1M In Fees From Purdue Ch. 11
- Biden Speech Pitches Investments To 'Win 21st Century'
- Ex-Katten Atty Caught In Shkreli Fraud Gives Up Law License
- GSK Says Amgen Patent Decision Will 'Devastate' Innovation
- Opioid Ad Blitz Targeted Not Just Docs But Insurers: J&J Rep
- Judge With 'West Virginia Grit' Takes On 1st Opioid MDL Trial
- Rite Aid Shoppers Nab Partial Cert. In 'Rapid Release' Ad Fight
- Atlanta TV Station Escapes Doc's Suit Over Stem Cell Reports
- In Agency First, FDA Says Co. Failed To Submit Trial Data
- Pharma Cos. Can Expect Harsh Antitrust Scrutiny From Biden
- J&J, Imerys Beat $117M Talc Verdicts Over Flawed Testimony
- Baylor, Gensetix Agree To Drop Cancer Patent Fight For Good
- Long-Running MRI Patent Row Settles Days Before Ill. Trial
- Bayer Rips 'Pay To Appeal' Charge In 11th Circ. Roundup Case
- Pfizer Tells Court Allele Wrong On Hatch-Waxman Safe Harbor
- Dr. Reddy's Says Amarin Delaying Heart Drug Competition
- Justices' Restitution Order May Allow FTC-Surescripts Deal
- Chancery OKs Keker Van Nest $19.6M Fee In Shire Ruling
- Indivior Finalizes $300M Deal To End Suboxone Cases
- HHS Eases Prescribing Rules For Opioid Addiction Meds
- Endo Says FTC Is Overreacting To Latest Impax Opioid Deal
- Maine Says Medical Pot Rule Doesn't Flout Commerce Clause
- Esperion Settles Investors' Cholesterol Drug Row For $18M
- J&J Sales Rep.'s Suit Says Male Workers Treated Better
- Teva Calls DOJ Questions About Morgan Lewis Work Intrusive
- AGs Warn Against Sanctioning Calif. In Generics Pricing MDL
- Newborn Opioid Victim Group Says Purdue Docs Lack Info
- PTAB Slashes 2 Bio-Rad DNA Patents In 10X Genomics Fight
- Pet Products Maker, Distributor Agree To End Antitrust Suit
- PTAB Upholds Oral Imaging Patent Involved In Dental IP Row
- Mylan Can Deduct Patent Suit Legal Fees, Tax Court Says
- Coronavirus Regulations: A State-By-State Week In Review
- Fed. Circ. Says J&J Unit's HIV Treatment May Enter Duty-Free
- Colgate Urges 2nd Circ. To Reverse $300M ERISA Suit Loss
- The Pandemic's Bright Spots For Lawyers Who Are Parents
- CBD Co. Dodges Counterclaims From Ex-Consultant, For Now
- There Are Other Crises Too, Opioid Maker Argues
- After USPTO, Iancu Isn't Done Advocating For Patent System
- Dental Suppliers Settle Antitrust Dispute Ahead Of Trial
- Strong IP Protection A Priority For Current, Ex-USPTO Heads
- Pot Cos. Sue Miami Over Dispensary Permit Denial
- DOJ Wants More Info On Morgan Lewis' Glenmark, Teva Work
- Pfizer 'Bonus' Irks Judge In Bristol-Myers Cancer IP Dispute
- Amazon Wants Ex-Worker's Contract Claim Axed In Pot Row
- Tenn. Can Impose Abortion Rule For Now, 6th Circ. Rules
- COVID Vaccine Maker, Jessica Alba's Startup Launch IPOs
- Risk-Based Compliance Improves Cannabis M&A Prospects
- Biden To Divert AstraZeneca Materials To India
- Wachtell, S&C Direct $7B Deal For Specialty Chemicals Co.
- Distributors Lose Pretrial Attack On W.Va. Opioid Damages
- EU Taking AstraZeneca To Court Over COVID Vaccine Supply
- FTC Calls In-House Ilumina Case As Important As Fed. Trial
- What Opioid Crisis? Drugmakers Test Bold Claim In Calif. Trial
- DC Circ. Struggles With FDA Stance Over Electric Shock Ban
- Chancery Awards BioPharm Co. $38M For Fraud-Tainted Deal
- Fed. Circ. Won't Rehear Amgen Drug Patent Fight
- Covidien Urges 1st Circ. To Reconsider Ex-Exec's Patent Win
- Pharma Co.'s $4.8M Investor Deal OK'd, But Fees Undecided
- How Tuna Antitrust Ruling Affects Job Bias Class Actions
- What High Court Is Considering In Assignor Estoppel Case
- Medical Device Biz Fight Mostly Belongs In Wis., Court Says
- UK Judge Won't Invalidate Alcon's Glaucoma Treatment Patent
- FDA Lifts Pause On J&J COVID Vaccine Following Panel Vote
- Health Hires: Nelson Mullins, Holmusk, Eledon
- Gilead, Shire Beat FCA Suits In NJ Over Marketing Programs
- Revise Mansfield Diversity Mandates To Also Benefit Veterans
- 11th Circ. Finds Expert Qualified In Suit Over Surgery Tool
- UK Litigation Roundup: Here's What You Missed In London
- IP Forecast: Supercell Preps For Another Clash With Gree
- Mo. Atty Agrees To Pay $137K To End SEC's Pot Fraud Suit
- Cooley-Led NeuroPace Raises $102M After Brief CFIUS Pause
- J&J's Chief Patent Atty Says COVID IP Waiver Won't Work
- Coronavirus Litigation: The Week In Review
- Gilead Whistleblower Dinged For Lost Texts In Kickbacks Suit
- Pot Co. Verano To Spend More Than $200M On Pa. Business
- Deals Rumor Mill: Toshiba, Discord, Oxford Nanopore
- 5th Circ. Finds Chemo Drug Hair Loss Claims Filed Too Late
- GenMark Investor Wants Records On $1.8B Roche Deal
- L'Oreal Won't Face 'Subjective' Claims In UMass Cream Suit
- Justices Eye Narrowing Bar On Patent Attacks, Not Ending It
- FDA Highlights Shortfalls At COVID-19 Vaccine Plant
- Cooley-Led Workplace Software Firm Leads Trio Of Tech IPOs
- 3rd Circ. Won't Revive Kodak Claims After Ch. 11 Discharge
- Pot Co. TerrAscend Picks Up Pa. Dispensaries In $70M Deal
- Impax, Endo Say FTC's Win Doesn't Help Opana Buyers
- What FTC Victory Means For Reverse Payment Settlements
- EPA Asked To Ban Pesticide After Species Harm Report
- Locke Lord Can't Ax $30M Malpractice Suit Under Anti-SLAPP
- AIG Prevails In Suit Over Coverage Of Clinic's $9M Abuse Deal
- Dana-Farber Asks High Court To Ignore Cancer IP Row
- 8th Circ. Backs Creighton's Win In Med Resident's Bias Suit
- GSK Engages In Systemic Age Discrimination, Suit Says
- Possible 'Showstopper' Ruling Looms In GSK Birth Defect Suit
- Fed. Circ. Tosses 'Unusual' Appeal On Menopause Drug IP
- Facing $50B Trial, Drugmakers Minimize Roles In Opioid Sales
- Judge Says Insolvency Protects Telehealth Co. From Sanction
- Biden Admin. Slammed For Nixing WTO Critical-Drug Proposal
- Philips' Chinese Rivals Can't Dodge Ill. Trade Secrets Suit
- Walgreens Hit With 'Pink Tax' Suit Over Hair-Loss Meds
- 7th Circ. Rules Insurer Has No Duty To Cover $3.3M TCPA Deal
- Pot Co. Jushi's M&A Tear Continues With $5M Buy In Ohio
- BentallGreenOak Raises $1.8B Europe Real Estate Fund
- FDA Faces Fresh Drug-Device Headaches After DC Circ. Loss
- FTC's Challenge To $8B Illumina Merger Shipped To Calif.
- Chicago Pushes For Opioid Trial But Pharma Wants More Time
- 5th Circ. Affirms Win For Sanofi In Chemo Hair Loss Suit
- GOP Reps Introduce Bill To Get Vaccines To Citizens First
- DLA Piper Adds Benefits, Exec Comp Partner From Cooley
- Mapping The Predicate Chain For Medical Device Approval
- Illumina Can't Shake Off Lab's Suit Over Use Of 'Illuminox'
- Profs, Orgs Tell Justices To Review Sham Litigation Exception
- 11th Circ. Panel Dubious Of Pfizer Marketing Challenge
- 2nd Circ. Won't Revive Off-Label Ad Suit Against Taro
- Jones Day Nabs Venable Trial Atty In LA
- Coronavirus Regulations: A State-By-State Week In Review
- Bankruptcy Litigation Could See More Third-Party Funding
- $50B Opioid Trial Starts With Warring Views Of Drug Marketing
- RelayHealth's $10M Deal In E-Prescription Antitrust Case OK'd
- LA City Atty Gets $1.2M Penalty, Injunction Against Vape Co.
- Chinese National Gets 33 Months For Lab Trade Secret Theft
- Sens. Want Expert Panel To Guide $100B Plan For R&D
- Fed. Circ. Ruling Won't Lead To Patents On DNA, Justices Told
- Walmart Punished In Opioid MDL For Discovery Defiance
- Ill. Dental Office Asks 7th Circ. To Revive COVID Coverage Bid
- Solar Tracking Co. Tops 4 IPO Launches Totaling $705M
- Royalty Pharma GC Says Law Limits Overcharge Payback
- McCarter & English Picks Up IP Attys From Mintz Levin
- Biotech Biz Founder's Exit Deal Fight Moves On In Chancery
- Wiggin & Dana Adds Life Sciences-Focused IP Partner
- States Must Factor Race In COVID-19 Vaccine Prioritization
- 5 Key Details As Drugmakers Face $50B Opioid Trial In Calif.
- Investors Get $17M To End Suit Over $446M Nutraceutical Buy
- Opana Buyers Point To FTC's 5th Circ. Win Against Impax
- Ex-Katten Atty's Retirement Accounts Can Be Garnished
- Quinn Emanuel, Other Firms Sue MiMedx Over Legal Fees
- Law360's Guide To Biden's Judicial Picks
- FDA Loses DC Circ. Appeal In Imaging Liquid Regulation Fight
- Late Bid For New Suboxone Antitrust Complaint Falls Flat
- Allele Urges Court Not To Toss IP Suit Over Pfizer Vaccine
- AstraZeneca Notches FTC Approval For $39B Alexion Deal
- 5 Firms Lead Trio Of Biotech IPOs Raising $721M Combined
- WFH And DIY May Spell Uptick In Consumer Product Suits
- Lessons From Federal Fraud Charges Against UBiome
- EPA OIG Says Trump Admin. Hid Health Risks From Ill. People
- AdventHealth Seeks $1.5M After PPE Fraud Settlement Default
- Why The Future Law Firm Model Is Industry-Based Offerings
- 9th Circ. Shows How Stats Shore Up Rejection Of Class Cert.
- Health Hires: Sheppard Mullin, Oncternal Therapeutics
- Biden Tops 100 Vacancies As Pa. Judge Takes Senior Status
- CBD Maker Says Ex-Partners Can't Land Quick Win In IP Row
- 6 D&O Provisions To Consider When Buying SPAC Insurance
- UK Litigation Roundup: Here's What You Missed In London
- Relay Therapeutics Inks Up To $270M Drug Discovery Co. Buy
- What To Watch As Justices Eye Restriction On Patent Attacks
- Manatt Phelps Vet, A Top Biden Health Pick, Hits Capitol Hill
- Roche Challenges $171M Patent Judgment At Federal Circuit
- Pharma Co. Says PE Firm Owes $6.7M After Merger
- Health Co. Fights Dismissal Bid For $5M Virus Coverage Suit
- IP Forecast: Ferring, Lupin To Face Off In Clenpiq Patent Trial
- Amgen Tells Full Fed. Circ. Antibody IP Ax Dooms Biologics
- How Companies Should Respond To Patent Diversity Bill
- Vein Filter Co. Slams 'Harassing' Financial Discovery Order
- Anesthesiology Org. Hit With Libel Suit Over Drug Articles
- 'New Breed' Of NPEs Spurs Increase In Patent Cases In Q1
- 3 Firms Assemble Thermo Fisher's $20.9B PPD Purchase
- 9th Circ. Urged To Revive Health Care Co.'s Trade Secrets Suit
- USPTO Launches Fast, Free Appeals On Virus Patent Apps
- Investor Notches Partial Win In Del. Suit For Biogen Records
- Surgical Co. Says Insurer's J&J Suit Coverage Is Still Disputed
- CDC Panel Punts On J&J Coronavirus Vaccine Pause
- Drug Exclusivity Bill Meant To Help Generics Sent To Biden
- J&J Investors Urged To Reject CEO Pay Over Opioid Litigation
- Florida Grower Says Pot Co. Tilray Sabotaged Applications
- Miss. Medical Pot Measure Faces Fire From State Justices
- USTR Tai Hints At IP 'Modifications' To Aid Vaccine Rollout
- PharMerica Must Face FCA Claims Over Electronic Data
- Pharma Co. Sues Zurich Unit To Cover $30M In Spoiled Vials
- Defending Against 'Entrepreneurial Model' Class Actions
- Mass Tort Defendants Exploit Bankruptcy Rules To Avoid MDL
- NHS Fights To Revive £220M Drug Patent Suit At Top UK Court
- Enforcement Takeaways From ABA Antitrust Meeting
- 4th Circ. Revives Antitrust Suit Over Actelion's Drug Tracleer
- US Sees 'Very Similar' Issues In J&J, AstraZeneca Vaccines
- 5th Circ. Backs FTC In First Post-Actavis Pay-For-Delay Case
- IHS Beats Wash. Tribe's Health Costs Suit At DC Circ.
- SEC's Latest Guidance Likely To Further Slow SPAC Market
- Speculation Abounds As Biden Is Slow To Nominate FDA Head
- 4th Circ. Says 'Vagisan' TM Confusingly Similar To 'Vagisil'
- Abortion Pill Visit Rule Lifted During Pandemic
- Thought Leadership's Critical Role In Law Firm Diversity
- Lens Buyers Urge OK For $9.3M Fee Award In Price-Fix MDL
- Alsup Trims Drug Co. Investors' Cancer Treatment Study Suit
- Mallinckrodt Slams Bid To DQ Arnold & Porter In Its Ch. 11
- Coronavirus Regulations: A State-By-State Week In Review
- Claims Trimmed In Suit Over Faulty Vein Filter Implant
- Rare Blood Clots Prompt Pause Of J&J COVID Vaccine
- Biden Taps Lowenstein Sandler Atty, Ex-NJ AG To Run DEA
- False Ad Suit Against Stem Cell Clinic Back In Ga. State Court
- NJ Pot Regulators Prioritize Equity, Patients' Access
- Amgen Urges Justices To Leave Enbrel Patent Ruling Alone
- 7 Cos. Restock Pipeline With IPOs That Could Exceed $2.1B
- Rite Aid Beats Suit Over Ex-Atty's Insider Trading Warning
- Law360's 2021 Life Sciences Editorial Board
- The Right Approach To Personal Jurisdiction In Class Actions
- Minn. House Panel OKs Legalizing, Taxing Recreational Pot
- Where Health Care Enforcement Is Headed Under Biden
- Full 6th Circ. Set To Look At Tenn. Abortion Fight
- NJ Justices Won't Step Into 3rd Circ. Pelvic Mesh Fee Row
- Bayer Sued Over Flea And Tick Collars Tied To Pet Deaths
- Bang Energy Drink Maker Avoids Sanctions In False Ad Suit
- Ketone Supplement Co. Hits Rival With IP Suit
- SmileDirect Tells 9th Circ. 'Harassment' Continues In Calif.
- LA Fitness Launches $500M Fight Against 11 Insurers
- Drugmaker MannKind Escapes Investors' Suit At 9th Circ.
- NJ Judge Denies Class Cert. For Generic Lamictal Buyers
- Biden Seeks $132B For HHS In War Against COVID, Opioids
- 6th Circ. Upholds IRS Summons For Cannabis Biz Docs
- Perrigo Execs Ask Out Of Investor Lawsuit Over $1.9B Tax Bill
- Health Hires: Morgan Lewis, K&L Gates
- Parents Want Wholesaler Sanctioned In Drug Death Suit
- WTO Head Calls For More Vaccines To Developing Countries
- 4 Firms Guide Clinical Stage Pharma Cos. In $221M IPOs
- What Associates Should Consider Before Switching Practices
- Key Takeaways From FDA Warnings To CBD Cos.
- 3rd Circ. Revives LivaNova Bacteria Exposure Suit
- FTC Says Moving Illumina Suit To Calif. Is Risky Amid COVID
- Medical Pot Co. Sues Detroit Over School Zoning Decision
- Brenntag Agrees To Shell Out $2.3M To Wrap 401(k) Suit
- Wilson Sonsini Adds Ex-Shearman & Sterling Partner In Austin
- 9th Circ. 'Directly Supports' Zetia Class Fight, 4th Circ. Told
- Opioid Judge Withdraws After AbbVie Elevates His Atty Sister
- Scott + Scott To Rep Precigen Investors In Gas Fraud Suit
- Purdue Wants Another Month's Reprieve From Opioid Suits
- Real Estate Rumors: Ocean Bank, Blackstone, General Capital
- Minerva Calls Assignor Estoppel 'Ill-Conceived Atextual' Error
- Ambry Genetics Gets Data Breach Suit Axed, For Now
- Covidien Can't Score Patents From Ex-Worker, 1st Circ. Says
- Fed. Circ. Upholds No-Contempt Finding In Oxygen Mask Case
- Full Fed. Circ. Told Newer Amgen Drug Patent Was 'Trivial'
- Mitigating Anti-Kickback Risks Of Health Tech Stock Warrants
- Outdated Experts Doom Suit Tying Diabetes Drug To Cancer
- Execs Sued By SEC No 'Mailroom' Underlings, 1st Circ. Says
- Ex-CBD Exec Says Co. Shorted Pay, Skimped On Expenses
- Teva Unit Urges Fed Circ. To Revive ADHD Drug Row
- 4 Effective Ways To Prioritize Client Advocacy
- Lab Supplier Says Wrong Co. Sued Over Faulty COVID Tests
- FDA Letters Suggest Scrutiny Of Virus And Vaping Products
- Eversheds Sutherland Nabs IP Partner From Wilson Sonsini
- States Too Late To Question Report In MDL, Drugmakers Say
- Opioid MDL Judge Picks New Bellwethers, Denies Retaliating
- Ga. Talc Co. Says Strict Liability Claims Over Cancer Too Late
- Endo Hit With Default Judgment In Tenn. Opioid Baby Suit
- Fed. Circ. Judge Doubts ITC Erred In Microfluidic Chip Case
- Abortion Provider Secures Win To Block Activist's Videos
- Arkansas Mayor Sues Pot Co. Harvest Over Moved Grow
- 2nd Circ. Questions Takeda's 'Lazarus' Take On Drug Patents
- A Breakdown Of The PTAB Backlog Arthrex Caused
- Remote Law Firm Culture Should Prioritize Associate Training
- Illumina Hits Back At FTC, Says $8B Grail Deal Can Save Lives
- Locke Lord Asks Texas Panel To End $30M Malpractice Suit
- Goodwin Picks Up 3 New Partners In Antitrust, Life Sciences
- COVID Vaccine Hopeful Lands $100M In Funding Round
- 9th Circ. Finds Robot Surgery Suit Time-Barred
- Rite Aid Shopper Wants Class Cert. In 'Rapid Release' Ad Fight
- Business Groups Ask High Court To Review $2.1B J&J Verdict
- Fox News Must Face Ex-Ad Client's Accounting Scheme Suit
- Quest Says Ex-Amazon Worker's Medical Marijuana Suit Fails
- Calif. AG Says Sanctions Rec. 'Misunderstands' Generics MDL
- Election Yields 1st Union At Rhode Island Dispensary
- Walgreens Claims Crowell Betrayed It With Humana Suit
- Coronavirus Regulations: A State-By-State Week In Review
- Fed. Circ. Probes Alleged Misconduct In DNA Tech IP Fight
- Lax Contemporaneity Test Could Buoy Insider Trading Claims
- Mo. Says Pot Exec Can't Sue Over Residency Rules
- Ways Universities Can Improve Foreign Influence Compliance
- Virtual Litigation May Unravel The Narcissistic Lawyer
- Purdue Judge Wary Of Changing Reasons For Ch. 11 Probe
- FDA Alum Heads To Cooley Amid Active Life Sciences Scene
- Reaching The Post-Amgen High Bar For Antibody Patents
- AstraZeneca Escapes Suit Claiming Drug Caused Gangrene
- Ex-CMS Worker, DOJ Say Insider Trading Conviction Must Go
- 9th Circ. Revives Claims That Medtronic Skirted FDA Review
- Black-Owned IT Biz Says It Was Dumped From $10M Pa. Deal
- CVS Wants Tribe To Arbitrate Prescription Reimbursement Suit
- Colorado-Based Biotech Co. Grabs $150M In Series E
- Teva, Pharmacies Want Humana's Copay Fraud Claims Tossed
- Mallinckrodt Gets OK For Up To $35M In Exec Bonuses
- Fintech Seeks $2B Valuation In Latham, Davis Polk-Led IPO
- Biz Groups Flock To Support Appeal Of $75M Dicamba Verdict
- Justices Won't Revive Teva-IBSA Thyroid Drug Patent Fight
- 2 Ways High Court Could Reshape Patent Assignor Estoppel
- Illumina Wants FTC's Suit Over $8B Grail Deal Moved To Calif.
- Pharmacies Can't Escape More Trials In Opioid MDL
- Trulieve Acquires Pa. Pot Shops In $60M Deal
- ABA Remote Work Guide Raises Bar For Atty Tech Know-How
- How NY's Cannabis Legalization Act Prioritizes Equity
- Pharmacies Take Swipe At Judge Amid Tightening Opioid MDL
- Ill. Court Says Plastic Co. Must Pay For Chemical Plant
- AndroGel Makers, Buyers Clash Over FTC Getting Discovery
- Shkreli Balks At Ban From Leading Public Co., $1.4M Fine
- GAO Won't Revisit Ruling Backing VA Nuclear Medicine Deal
- Univ. Hospitals Say Positive COVID-19 Tests Trigger Coverage
- 'Ignore The Man Behind The Curtain' Won't Fly In COVID Suit
- Lateral Hire Conflict Screening Lessons From DLA Piper Case
- Health Hires: King & Spalding, Ropes & Gray
- Boston Drug Discovery Co. Grabs $75M In Series C
- 3rd Circ. Preview: Workplace, Insurance Rows Highlight April
- 11th Circ. Says Not Enough Evidence For Hysterectomy Suit
- National Black Farmers' Roundup Suit To Stay In Calif. MDL
- Vagisil Maker Gets Rival's 'Vagisert' TM Blocked At TTAB
- Big Pharma Tells Justices To Keep Assignor Estoppel
- Illumina Agrees To Delay $8B Grail Deal During FTC Challenge
- March IPOs Exploded, But The Boom Is Starting To Slow
- SEC, Ex-Katten Partner Reach Deal In Shkreli Fraud Suit
- Perrigo Hid $1.9B Tax Bill, Class Says In Seeking Fast Win
- Miss. High Court Won't Ax AG's J&J Talc False Ad Suit
- Bristol Myers Squibb Settles Medicaid Rebate Suit For $75M
- Ill. Court Says Suit Over Failed Shire Merger Rightly Tossed
- Deals Rumor Mill: Kioxia, Raizen, Bayer
- FDA Accused Of Brushing Off Safety Issues At Merck Plant
- SDNY Ruling Opens Door To Class Challenges In 2nd Circ.